- Home
- IGC vs NMTC Comparison
IGC vs NMTC Comparison
Compare IGC & NMTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGC
- NMTC
- Stock Information
- Founded
- IGC 2005
- NMTC 2009
- Country
- IGC United States
- NMTC United States
- Employees
- IGC N/A
- NMTC N/A
- Industry
- IGC Biotechnology: Pharmaceutical Preparations
- NMTC Medical/Dental Instruments
- Sector
- IGC Health Care
- NMTC Health Care
- Exchange
- IGC Nasdaq
- NMTC Nasdaq
- Market Cap
- IGC 26.9M
- NMTC 27.7M
- IPO Year
- IGC N/A
- NMTC N/A
- Fundamental
- Price
- IGC $0.35
- NMTC $0.70
- Analyst Decision
- IGC Strong Buy
- NMTC
- Analyst Count
- IGC 2
- NMTC 0
- Target Price
- IGC $3.63
- NMTC N/A
- AVG Volume (30 Days)
- IGC 222.5K
- NMTC 140.0K
- Earning Date
- IGC 11-12-2024
- NMTC 12-12-2024
- Dividend Yield
- IGC N/A
- NMTC N/A
- EPS Growth
- IGC N/A
- NMTC N/A
- EPS
- IGC N/A
- NMTC N/A
- Revenue
- IGC $1,183,000.00
- NMTC $3,922,499.00
- Revenue This Year
- IGC N/A
- NMTC $109.53
- Revenue Next Year
- IGC $13.57
- NMTC $90.00
- P/E Ratio
- IGC N/A
- NMTC N/A
- Revenue Growth
- IGC N/A
- NMTC N/A
- 52 Week Low
- IGC $0.25
- NMTC $0.60
- 52 Week High
- IGC $0.91
- NMTC $2.00
- Technical
- Relative Strength Index (RSI)
- IGC 42.76
- NMTC 33.74
- Support Level
- IGC $0.33
- NMTC $0.65
- Resistance Level
- IGC $0.42
- NMTC $0.73
- Average True Range (ATR)
- IGC 0.02
- NMTC 0.07
- MACD
- IGC -0.00
- NMTC -0.02
- Stochastic Oscillator
- IGC 32.14
- NMTC 13.74
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
About NMTC NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.